|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Genetic testing revealed a somatic FN1-FGFR1 translocation in the FGF23-producing tumor causing TIO; however, a germline PTEN mutation was not identified.
|
29380000 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
This positive association of miR-17/92 with BCR-FGFR1 was also confirmed in primary mouse SCLL tissues and primary human CLL samples. miR-17/92 promotes cell proliferation and survival by targeting CDKN1A and PTEN in B-lymphoma cell lines and primary tumors.
|
29367757 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The level of FGFR1 amplification did not correlate with tumor stage, lymph node staging, or metastasis.
|
29351293 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
These results suggest that genomic alterations involving the cell cycle (TP53, CCND1, CDKN2A), as well as FGFR1 amplifications and tumour genomic alterations burden are prognostic biomarkers and might be therapeutic targets for patients with HNSCC.
|
29331751 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The presence of FGFR1 gene amplification was associated with patient age (65 versus 69 years, p = 0.046), but not with gender, tumor stage, histologic subtype, tumor grade, or ΔNp63/p40 immunoreactivity.
|
29270870 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
This rare case implies FGFR1 translocation in a precursor cell capable of differentiation into mast cells and lymphoblasts, strengthening the relationship between the 2 tumors in the World Health Organization classification: myeloid and lymphoid neoplasms with FGFR1 abnormalities, and SM with an associated hematologic neoplasm.
|
29107667 |
2018 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Translocations involving the fibroblast growth factor receptor 1 (FGFR1) gene are associated with the 8p11 myeloproliferative syndrome (EMS), a rare neoplasm that following a usually short chronic phase progresses into acute myeloid or lymphoid leukemia.
|
28881484 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The immunohistochemical results were as follows: the tumour cells were positive for FGF23 (nine of 12, 75%), FGFR1 (11 of 11, 100%), CD56 (12 of 14, 85.7%) and E26 oncogene homologue (ERG) (5 of 13, 38.4%).
|
28858396 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In estrogen-free conditions, FGFR1 associated with ERα in tumor cell nuclei and regulated the transcription of ER-dependent genes.
|
28751448 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
However, only about 11% of such <i>FGFR1</i>-amplified tumors respond to single-agent FGFR inhibition and several tumors exhibited insufficient tumor shrinkage, compatible with the existence of drug-resistant tumor cells.<b>Experimental Design:</b> To investigate possible mechanisms of resistance to FGFR inhibition, we studied the lung cancer cell lines DMS114 and H1581.
|
28630215 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
S49076 is an oral ATP-competitive inhibitor of MET, AXL, and FGFR1-3 receptors that is currently in phase I/II clinical trials in combination with gefitinib in NSCLC patients whose tumors show resistance to EGFR inhibitors.
|
28619752 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
It is important to recognize that neoplasms carrying the t(8;22)/BCR-FGFR1, although rare, can commonly with B lymphoblastic leukemia at the initial diagnosis, which could distract one from recognizing a possible underlying 8p11 myeloproliferative syndrome.
|
28551329 |
2017 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
In ependymomas, increased FGFR3 or FGFR1 expression was associated with high tumor grade, cerebral location, young patient age, and poor prognosis.
|
28468611 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The fgfr1 TuKO tumors showed significantly decreased primary tumor growth and, most importantly, greatly reduced metastasis to lung.
|
28433771 |
2017 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
In addition, NSENL as monotherapy or combined with DDP downregulated multidrug resistance-associated protein 1 (MRP1), basic fibroblast growth factor (bFGF) and fibroblast growth factor receptor 1 (FGFR1) at both the mRNA and protein levels ([Formula: see text]), reduced glutathione S-transferase π (GST-π) protein expression and tumor microvascular density as well as decreased phosphorylation of protein kinase B (Akt) and mammalian target of rapamycin (mTOR) ([Formula: see text]).
|
28231742 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Correlative studies included FGFR-1 amplification on archival tumour and serum samples for circulating angiogenesis factors.
|
28213002 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Moreover, msFGFR2c significantly inhibited the proliferation of FGFR1IIIc-positive NCI-H1299 lung cancer cells by the suppression of FGF-2-induced FGFR1 activation and suppressed the growth of NCI-H1299 transplanted tumors in nude mice.
|
28049184 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
To investigate the role of TUBB3 for development of genetic instability, we compared TUBB3 expression with histopathological features and surrogate markers of genetic instability and tumor aggressiveness; copy number changes of HER2, TOP2A, CCND1, RAF1, and FGFR1; nuclear accumulation of p53, and cell proliferation in a tissue microarray (TMA) with more than 700 bladder cancers.
|
28025079 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Notably, in two lung cancer models with FGFR1 amplification, the antitumor efficacy was higher, suggesting that the simultaneous inhibition of VEGF and FGF receptors in FGFR1 dependent tumors can be therapeutically advantageous.
|
27988457 |
2017 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
We performed whole exome (paired tumor and germline DNA) and transcriptome (tumor RNA) sequencing, which revealed somatic mutations in NF1 and FGFR1.
|
27862886 |
2017 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Our findings are consistent with the results of the TCGA data set for the "squamous-like" subtype of bladder cancer (n = 85), which revealed reduced overall expression of FGFR1 and FGFR2 in tumors compared to normal tissue, while expression of FGFR3 remained high.
|
27669755 |
2016 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
By contrast, 121 cases of potential morphologic mimics (belonging to 13 tumor types) rarely expressed FGFR1, the main exceptions being solitary fibrous tumors (positive in 40%), chondroblastomas (40%), and giant cell tumors of bone (38%), suggesting a possible role for FGFR1 immunohistochemistry in the diagnosis of phosphaturic mesenchymal tumor.
|
27443518 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
As a consequence, genetic or pharmacological inhibition of FGFR1 in combination with trametinib enhances tumour cell death in vitro and in vivo.
|
27338794 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
This case provides direct evidence to illustrate the clonal relationship of chronic phase and blast phase in myeloid neoplasms with FGFR1 rearrangement, and demonstrates that clonal cytogenetic evolution plays an important role in disease progression.
|
27283163 |
2016 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Together, genomic aberrations in FGFR/EGFR PI-3 kinase and RAS pathways were identified in 8 (80%) tumors and included mutually exclusive and potentially actionable activating FGFR1, PIK3CA and BRAF V600E mutations, inactivating TSC2 mutation, EGFR amplification and PTEN loss.
|
27255162 |
2016 |